Similarly among the recurrent tumors, IDH1/IDH2 mutation was detected in 77% (10/13) of LGGs, 61% (11/18) of anaplastic gliomas and 50% (11/22) of GBM, with 79% (11/14) of secondary GBM harbored the mutation. Here, IDH2 is linked to glioblastoma.